title: Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease.
abstract: BACKGROUND
  Gastroesophageal reflux disease (GERD) influences the symptoms of asthma with acid and oxidative stress.
  
  
  OBJECTIVE
  The purpose of this study was to determine the usefulness of measurement of the acid stress marker pH and the oxidative stress marker 8-isoprostane by exhaled breath condensate in proton pump inhibitor (PPI) therapy effect on moderate asthma patients with GERD.
  
  
  METHODS
  The pH and the concentration of 8-isoprostane were measured in the exhaled breath condensate of patients with moderate asthma (n = 36) and healthy subjects (n = 26). Two months of PPI therapy (lansoprazole at 30 mg/day) were done in the asthma patients with (n = 13) or without (n = 13) GERD according to a questionnaire for the diagnosis of reflux disease, and exhaled markers were measured.
  
  
  RESULTS
  The pH was lower (7.3 +/- 0.3) and the 8-isoprostane level was higher (27.7 +/- 2.3) in the asthma patients than in the healthy control subjects (pH 7.5 +/- 0.2 and 8-isoprostane 6.6 +/- 1.2). Two months of PPI therapy improved the pH (from 7.2 +/- 0.1 to 7.3 +/- 0.1) and the 8-isoprostane concentration (from 32.7 +/- 3.4 to 19.2 +/- 3.4) in the asthma patients with GERD, along with improvement of GERD symptoms. However, these markers did not change in the asthma patients without GERD.
  
  
  CONCLUSIONS
  Measurement of the pH and 8-isoprostane level of exhaled breath condensate may be useful to evaluate the influence of GERD on asthma, as well as to determine the timing of intermittent PPI therapy.
authors: Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma, Japan. yasuos@med.gunma-u.ac.jp
authors: Yasuo
authors: Y
authors: Shimizu
authors: Kunio
authors: K
authors: Dobashi
authors: Jian Jun
authors: JJ
authors: Zhao
authors: Tadayoshi
authors: T
authors: Kawata
authors: Akihiro
authors: A
authors: Ono
authors: Noriko
authors: N
authors: Yanagitani
authors: Kyoichi
authors: K
authors: Kaira
authors: Mitsuyoshi
authors: M
authors: Utsugi
authors: Takeshi
authors: T
authors: Hisada
authors: Tamotsu
authors: T
authors: Ishizuka
authors: Masatomo
authors: M
authors: Mori
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000453:epidemiology*; D015415:Biomarkers / Q000032:analysis; D001944:Breath Tests; D015897:Comorbidity; D015237:Dinoprost / Q000031:analogs & derivatives / Q000032:analysis; D005260:Female; D005764:Gastroesophageal Reflux / Q000453:epidemiology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D054328:Proton Pump Inhibitors
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D015415:Biomarkers; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost